October 30th 2024
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
October 30th 2024
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer
November 15th 2020Patients who received palbociclib and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients who received placebo and fulvestrant, according to an exploratory subgroup analysis of the phase 3 PALOMA-3 trial.
Read More
Hormone Receptor, pCR May Point to Survival on Dual HER2 Blockade
November 11th 2020Updated data reported from a phase 3 trial show that patients with HER2- positive early breast cancer had better rates of overall survival after experiencing a pathologic complete response on HER2-targeted therapy, and these responses were observed most often in those with hormone receptor–negative status.
Read More
Phase 3 Study Initiated to Explore Adjuvant Trastuzumab Deruxtecan in HER2+ Breast Cancer
November 10th 2020A phase 3 study was initiated for a head-to-head comparison of trastuzumab deruxtecan versus T-DM1 as adjuvant treatment of a subset of patients with HER2-positive early breast cancer.
Read More
TNBC Heterogeneity Opens Door for Emerging Targeted Therapies
October 26th 2020As a greater understanding of triple-negative breast cancer heterogeneity develops over time, combinations of PD-1/PD-L1 plus PARP inhibitors, androgen receptor targeted agents, and PI3K/AKT/mTOR pathway inhibitors are undergoing evaluation by investigators in the field.
Read More
Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast Cancer
October 22nd 2020Recent acceleration in the introduction of new regimens for the treatment of estrogen receptor–positive breast cancer has led to significant survival enhancement, but questions remain regarding how patients should be stratified following disease progression with these therapies.
Read More
Investigators Tailor TNBC Therapy Using Genomic Alterations
October 21st 2020In a presentation at the 2020 Lynn Sage Breast Cancer Symposium, Virginia G. Kaklamani, MD, DSc, reviewed the current genomic tools in the triple negative breast cancer landscape that predict response to targeted treatments.
Read More
Expert Insights on Metastatic Breast Cancer Awareness Day: Treating Patients by Subtype
October 13th 2020A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.
Read More
Leading Research From ESMO 2020 Further the Potential of Targeted Agents in Breast Cancer
October 9th 2020Breast cancer data reported during the 2020 European Society Medical Oncology Virtual Congress revealed major advances in the treatment paradigm. The agents included in these trials challenged that standard-of-care.
Read More
Palbociclib Combination Misses Primary End Point of PENELOPE-B in HR+, HER2- Early Breast Cancer
October 9th 2020Palbociclib in combination with standard endocrine therapy did not improve invasive disease-free survival in patients with hormone receptor-positive, HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy, missing the primary end point of the phase 3 PENELOPE-B trial.
Read More
FDA Recommends Clinical Trials Include Premenopausal Women With Breast Cancer
October 8th 2020The FDA issued a draft guidance that encourages the inclusion of premenopausal women with breast cancer in clinical trials, which will in order tohelp researchers determine the efficacy of a hormonal drug or biological products for this population along with others.
Read More
The Need for Genomic Testing Recognized During Breast Cancer Awareness Month
October 1st 2020In an interview with Targeted Oncology, Daniel A. Vorobiof, MD, discussed the evolution of the breast cancer treatment landscape and the emerging role of genomic testing in this space during Breast Cancer Awareness Month.
Read More
FDA Grants Fast Track Designation to Eganelisib Combination in TNBC
September 29th 2020A Fast Track designation was granted by the FDA to eganelisib in combination with an immune checkpoint inhibitor and chemotherapy for the first-line treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer.
Read More
Palbociclib/Fulvestrant Prolongs PFS in Endocrine-Sensitive, HR+/HER2– Metastatic Breast Cancer
September 21st 2020Patients with endocrine-sensitive hormone receptor–positive, HER2-negative metastatic breast cancer, treated with Frontline fulvestrant in combination with palbociclib experienced improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone, achieving the primary end point of the phase 2 FLIPPER trial.
Read More
In High-Risk Early Breast Cancer, Risk of Recurrence Is Reduced With Abemaciclib
September 20th 2020Findings from the phase 3 monarchE trial reported at the ESMO Virtual Congress 2020 showed that the risk of invasive disease with abemaciclib plus endocrine therapy was significantly reduced versus endocrine therapy alone in patients with high-risk early hormone receptor-positive, HER2-negative breast cancer.
Read More
Responses Significantly Improved With Atezolizumab Regimen in Triple-Negative Breast Cancer
September 20th 2020The pathologic complete responses were significantly improved with neoadjuvant atezolizumab in combination with nab-paclitaxel plus doxorubicin and cyclophosphamide compared with placebo and chemotherapyin patients with stage 2 or stage 3 triple-negative breast cancer.
Read More
Significant Benefit Observed in HR+/HER2- Breast Cancer With Dose-Dense iddEPC
September 20th 2020Patients with HR-positive, HER2-negative breast cancer experienced significant benefit when treated with neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide.
Read More
Abemaciclib Doublet Demonstrates OS Benefit in HR+, HER2- Metastatic Breast Cancer
September 20th 2020Abemaciclib in combination with tamoxifen led to an improvement in overall survival compared with abemaciclib alone in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Notably, the benefit of the combination was observed across all subgroups in the study, according to findings from the final OS analysis of the nextMONARCH trial presented during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Alpelisib and Fulvestrant Show Benefit for Breast Cancer Subgroups in SOLAR-1
September 19th 2020Postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer in the SOLAR-1 trial experienced prolonged overall survival with alpelisib and fulvestrant even though the study did not cross the prespecified O’Brien-Fleming efficacy boundary (P ≤ .0161), according to research presented at the 2020 ESMO Virtual Congress.
Read More
NeoTRIPaPDL1 Trial Showed TIL Activity With Guidance From PD-L1 Status
September 19th 2020The combination of atezolizumab, carboplatin, and nab-paclitaxel increased pathological complete response by 10% or more in “immune-rich” patients with high-risk and locally advanced triple-negative breast cancer, as well as turned PD-L1 negative tumors positive most patients treated with immunotherapy, according to the phase 3 NeoTRIPaPDL1 trial data presented at the 2020 ESMO Virtual Congress.
Read More
Ipatasertib Combination Misses End Points in HR+ HER2- Advanced Breast Cancer
September 19th 2020An improvement in progression-free survival and objective response rate was not observed with the addition of ipatasertib to paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.
Read More